Skip to main navigation Skip to search Skip to main content

APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024

  • George Lau
  • , Shuntaro Obi
  • , Jian Zhou
  • , Ryosuke Tateishi
  • , Shukui Qin
  • , Haitao Zhao
  • , Motoyuki Otsuka
  • , Sadahisa Ogasawara
  • , Jacob George
  • , Pierce K.H. Chow
  • , Jianqiang Cai
  • , Shuichiro Shiina
  • , Naoya Kato
  • , Osamu Yokosuka
  • , Kyoko Oura
  • , Thomas Yau
  • , Stephen L. Chan
  • , Ming Kuang
  • , Yoshiyuki Ueno
  • , Minshan Chen
  • Ann Lii Cheng, Gregory Cheng, Wan Long Chuang, Oidov Baatarkhuu, Feng Bi, Yock Young Dan, Rino A. Gani, Atsushi Tanaka, Wasim Jafri, Ji Dong Jia, Jia Horng Kao, Kiyoshi Hasegawa, Patrick Lau, Jeong Min Lee, Jun Liang, Zhenwen Liu, Yinying Lu, Hongming Pan, Diana A. Payawal, Salimur Rahman, Jinsil Seong, Feng Shen, Gamal Shiha, Tianqiang Song, Hui Chuan Sun, Tsutomu Masaki, Ekaphop Sirachainan, Lai Wei, Jin Mo Yang, Jose D. Sallano, Yanqiao Zhang, Tawesak Tanwandee, AKadir Dokmeci, Shu Sen Zheng, Jia fan, Sheung Tat Fan, Shiv Kumar Sarin, Masao Omata
  • Fudan University
  • Teikyo University Chiba Medical Center
  • Graduate School of Medicine
  • Nanjing University of Chinese Medicine
  • Peking Union Medical College Hospital
  • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
  • Chiba University Graduate School of Medicine
  • University of Sydney
  • National Cancer Centre, Singapore
  • Chinese Academy of Medical Sciences & Peking Union Medical College
  • Juntendo University
  • Kagawa Univerisity
  • University of Hong Kong
  • Chinese University of Hong Kong
  • Sun Yat-Sen University
  • Yamagata University Faculty of Medicine
  • Sun Yat-Sen University Cancer Center
  • National Taiwan University College of Medicine
  • Humanity and Health Clinical Trial Center
  • University of Macau
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Mongolian National University of Medical Sciences
  • Sichuan University
  • National University Health System
  • Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
  • Teikyo University School of Medicine
  • Aga Khan University
  • Beijing Friendship Hospital, Capital Medical University
  • Seoul National University College of Medicine
  • Peking University International Hospital
  • Army General Hospital
  • Chinese PLA General Hospital
  • Zhejiang University School of Medicine
  • Fatima University Medical Center Manila
  • Bangabandhu Sheikh Mujib Medical University
  • Yonsei University College of Medicine
  • Second Military Medical University
  • European Liver Patients' Association
  • World Hepatitis Alliance
  • African Liver Patient Association (ALPA)
  • Faculty of Medicine
  • Peking Union Medical College
  • Tsinghua University
  • College of Medicine of the Catholic University of Korea
  • University of Santo Tomas, Manila
  • The Fourth Affiliated Hospital of Harbin Medical University
  • Ankara University
  • Zhejiang Shuren University
  • Hong Kong Sanatorium and Hospital
  • Institute of Liver and Biliary Sciences
  • Yamanashi Prefectural Central Hospital

Research output: Contribution to journal › Article › peer-review

95 Citations (Scopus)

Abstract

In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)1661-1683
Number of pages23
JournalHepatology International
Volume18
Issue number6
DOIs
Publication statusPublished - Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Guidelines
  • Hepatocellular carcinoma
  • Systemic therapy
  • The Asian Pacific Association for the study of the liver

Fingerprint

Dive into the research topics of 'APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024'. Together they form a unique fingerprint.

Cite this